Advertisements

Жанин

Quick links to important sections

Жанин

Selected form

Advertisements
Advertisements

Method of action: Contraceptive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Жанин

Quick Facts

Property Description
Active Ingredients Ethinylestradiol (synthetic estrogen) and Dienogest (synthetic progestogen)
Form Film-coated tablet
Pharmacological Class Sex hormones and modulators of the genital system
Common Uses Prevention of pregnancy; Treatment of moderate acne
Origin Synthetic

What type of medicine is Жанин and what makes it unique?

Жанин (also known as the combination Ethinylestradiol/Dienogest) is a prescription combined oral contraceptive (COC). It is classified within the sex hormones and modulators of the genital system pharmacological class. This is a synthetic medication that utilizes the combined effect of two hormones to regulate the reproductive cycle.

A key feature of this specific formulation is the progestogen, Dienogest, which possesses antiandrogenic properties. This characteristic is why the medication is clinically recognized for both birth control and the secondary use of treating moderate acne in women who also elect to use oral contraception.


What hormones is Жанин made of and what is its primary purpose?

Жанин is a monophasic combination drug formulated as film-coated tablets for oral administration. Each active pill contains the same fixed dose of the synthetic estrogen, Ethinylestradiol, and the synthetic progestogen, Dienogest. This monophasic nature is designed to provide a consistent hormonal level throughout the active phase of the cycle.

The medication's main purpose is the effective prevention of pregnancy. The hormones work together to primarily suppress ovulation (the release of an egg), which is the principal mechanism of contraception. Additionally, due to its composition, the medicine is also indicated as a treatment option for moderate acne after failure of suitable local or oral antibiotic therapies.

Advertisements

What side effects are possible with Жанин?

Possible Side Effects and Safety Information

The official safety profile for Ethinylestradiol/Dienogest is structured to communicate the full scope of potential adverse reactions, ranging from frequently reported events to rare but serious risks, as documented in government regulatory sources. Adverse reactions are classified by incidence (frequency) and grouped by the body system affected (System-Organ-Class or SOC).

Frequency-Classified Adverse Reactions

The prescribing information classifies reactions based on their frequency in clinical studies:

  • Common (occurring in 1% to 10% of users): These effects commonly involve the Nervous System (e.g., headache, including migraine), Reproductive System (e.g., irregular uterine bleeding, breast pain), Gastrointestinal Disorders (e.g., nausea, vomiting, abdominal pain), and Metabolism (e.g., increase in body weight, acne).
  • Uncommon (occurring in 0.1% to 1% of users): Reactions may include dizziness, changes in mood or libido, skin discoloration (chloasma), or fluid retention.
  • Rare (occurring in less than 0.1% of users): These reports include clinically significant events such as venous or arterial thromboembolic events.

Serious Adverse Reactions and Safety Patterns

The use of combined oral contraceptives (COCs) is associated with warnings regarding serious adverse reactions. These include an increased risk of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Arterial Thromboembolism (ATE) (e.g., stroke). Other documented serious concerns are the development of benign or malignant Liver Tumors and certain Carcinomas.

Regarding exposure, the risk of VTE is highest during the first year of use or upon restarting after a break of four weeks or more. Unscheduled bleeding is more frequently observed during the initial three months of treatment.

Safety-Related Restrictions

The medication is formally contraindicated by regulatory bodies in women with a high risk of thrombotic diseases, severe liver disease or liver tumors, known hormone-sensitive malignancies, or migraine with focal neurological symptoms. Furthermore, it is not indicated for postmenopausal women or for use before the onset of menstruation (menarche).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for combined oral contraceptives containing ethinylestradiol and dienogest indicates that acute overdose is associated with mild, self-limiting effects. The condition is not likely to be life-threatening following acute ingestion, according to regulatory statements.

Documented Clinical Manifestations

Overdose exposure may result in hormone-related signs such as nausea and vomiting affecting the gastrointestinal system. Additionally, the regulatory documents specify genitourinary signs, including vaginal withdrawal bleeding, which may be delayed, and breast tenderness. These documented symptoms have been reported in adult females as well as in children following accidental ingestion of an excess amount.

Official Emergency Response

If an overdose is suspected, emergency medical attention must be sought immediately. Regulatory guidance mandates contacting a national Poison Help hotline to determine the necessary level of care. Since no specific antidote is known for the active ingredients, the management strategy is strictly symptomatic and supportive. This may involve clinical observation, monitoring of vital signs, and performing necessary blood and urine tests in a medical setting. This official management structure defines the overdose event as low-risk for acute severity while requiring mandatory immediate clinical reporting.

Advertisements

Therapeutic Uses of Жанин

The medication is used across multiple therapeutic domains: consistent contraception and the management of a specific dermatological condition. The combination in Жанин is considered relevant for women who require both support for contraception and management for moderate acne vulgaris.

It is primarily applied across the domain of reproductive health to assist with a consistent and long-term contraception management. It is relevant in contexts marked by the need for family planning, offering a therapeutic application that supports planning related to pregnancy prevention.

Additionally, it is commonly used to manage distressing symptoms related to systemic imbalance, specifically the inflammatory and non-inflammatory lesions of moderate acne, and is relevant for easing symptoms related to heavy menstrual bleeding (menorrhagia) and painful cramps (dysmenorrhea).

This provides supportive relief that helps patients cope more steadily and assists with functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Androgen-Related Symptoms Жанин is considered relevant for women seeking multiple therapeutic applications, addressing the need for support for contraception while also providing supportive management for visible moderate acne symptoms.

Regulatory References

  1. EMA therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Жанин, a medicine containing drospirenone and ethinyl estradiol, is an oral contraceptive with specific official eligibility requirements and numerous absolute contraindications defined by governmental regulatory documents. It should only be used by women who do not have any of the following restricted conditions.

Contraindicated Populations

Use is prohibited in females who have or have had:

  • High Risk for Blood Clots (Thrombotic Diseases): This includes a history of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, heart attack, or thrombogenic heart valve or rhythm disorders. It is also prohibited for women age 35 or older who smoke.
  • Organ Impairment: Liver tumors (benign or malignant), active liver disease, renal impairment, or adrenal insufficiency.
  • Cancer: Current diagnosis or history of breast cancer or other hormone-sensitive cancers.
  • Other Conditions: Uncontrolled hypertension, diabetes with vascular disease, specific severe migraine headaches, or undiagnosed abnormal uterine bleeding.

Other Eligibility Restrictions

  • Pregnancy/Lactation: Use is prohibited during pregnancy and breastfeeding.
  • Special Consideration: The drug must be discontinued before and after major surgery due to the increased risk of thromboembolism.
Advertisements

What should I know about interactions with other medicines?

The interaction profile for Жанин focuses on substances that formally alter the plasma concentration of its two active hormones, Ethinylestradiol and Dienogest, or pose specific safety risks in combination, as defined by regulatory documents.

Contraindicated Combinations

Co-administration with specific combination regimens for treating Hepatitis C is strictly contraindicated. This includes medicinal products containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, and combinations with Glecaprevir/Pibrentasvir or Sofosbuvir/Velpatasvir/Voxilaprevir. This prohibition is enforced due to the documented risk of significant elevations in liver enzymes.

Substances that Reduce Exposure

Certain medicinal products and supplements accelerate the clearance of the hormones via enzyme induction, reducing systemic exposure and potentially compromising efficacy. These include enzyme inducers such as the anticonvulsants Phenytoin and Carbamazepine, the anti-infective Rifampicin, and the herbal product St. John's Wort. The official regulatory constraint requires that a non-hormonal barrier method be used concurrently with any enzyme-inducing drug and for a period of 28 days following its discontinuation.

Substances that Increase Exposure

Conversely, strong inhibitors of the CYP3A4 metabolic pathway, such as Ketoconazole and Clarithromycin, may increase the plasma concentrations of the hormones by reducing their clearance. Furthermore, this medication can interfere with the metabolism of other co-administered drugs, potentially increasing the systemic exposure of medicines like Ciclosporin or decreasing the exposure of drugs like Lamotrigine.

Advertisements

Mechanism of Action

The combined oral contraceptive Жанин, containing Ethinyl Estradiol and Dienogest, acts through multiple layered biological mechanisms to regulate reproductive function.

Suppression of the Central Signaling Axis

The primary mechanism involves the negative feedback exerted by the synthetic hormones on the Hypothalamic-Pituitary-Ovarian (HPO) axis. This sustained hormonal signal suppresses the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) from the pituitary gland. This cascade prevents the natural peak of LH required to trigger ovulation, leading to a state of ovarian quiescence that results from the central HPO axis modulation.

Modulation of Local Reproductive Barriers

The progestin component, Dienogest, modulates key physiological systems in the lower reproductive tract. It causes the cervical mucus to become thicker and less penetrable, which physically obstructs sperm movement. Concurrently, it influences the endometrium (uterine lining) to become thinner and less developed. The thin, less-developed endometrium exhibits reduced receptivity.

Targeted Androgen Receptor Activity

The unique structure of Dienogest engages an ancillary mechanism by acting as an antagonist at certain androgen receptors in peripheral tissues. This action modulates androgen signaling at the cellular level.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Жанин

Жанин (Ethinylestradiol/Dienogest) is a combination oral contraceptive that must be taken strictly as directed by the established dosing schedule to maintain its efficacy. The product is administered via the oral route.

Dosing and Procedural Structure

The standard dosage is one tablet daily for 28 consecutive days, followed immediately by the first tablet of a new pack. This regimen typically consists of 21 active (hormone-containing) tablets followed by 7 inert (inactive) tablets.

  • Timing and Consistency: Take one tablet at approximately the same time every day, ensuring the interval between tablets is always 24 hours. The tablet order directed on the blister pack must be followed precisely. Administration can occur without regard to meals.
  • Starting the Regimen: For the first cycle, administration should begin on Day 1 of the menstrual cycle (the first day of the period). If starting later than Day 1, a non-hormonal back-up contraceptive method is required for the first 7 days of active pill use.
  • Postpartum Use: The initiation of the combined oral contraceptive must be delayed until at least 4 weeks after delivery in women who are not breastfeeding.

Missed Dose Instructions

If a dose is missed, immediate action is required to minimize the risk of diminished effectiveness. The following rules apply to active tablets:

  • One Active Tablet Missed: Take the missed active tablet immediately, as soon as it is remembered. Continue taking the remaining tablets at the regular time, even if it means taking two tablets in one day. No additional contraceptive protection is required.
  • Inactive Tablet Missed: Discard the missed inactive tablet(s) and continue taking one tablet daily. Starting the next active pack on schedule is crucial, and no back-up contraception is needed in this case.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Жанин

Evidence for Preventing Pregnancy (Contraception)

This section will summarize the structure of officially referenced clinical research available for the primary indication, focusing on the types of controlled trials and standardized outcomes (such as the Pearl Index and ovulation inhibition) that regulators rely on for this use.

The prevention of pregnancy was studied for the combination of Ethinylestradiol and Dienogest primarily through controlled clinical trials. Research examined highly specific and standardized outcomes, mainly the Pearl Index, which measures how many pregnancies occurred per 100 women using the medicine for one year. Studies also focused on confirming the fundamental effect of suppressing the body’s natural hormonal cycle to inhibit ovulation.

Findings describe patterns observed in the studies related to the inhibition of ovulation. The data show patterns related to consistent cycle control, which is the regular pattern of bleeding documented during the treatment period.

Evidence for Treating Moderate Acne Vulgaris

This part will review the scope of the clinical evidence supporting the secondary indication, including the design of controlled trials and the specific dermatological measures (like lesion counts and Investigator Global Assessment scores) used to evaluate the skin condition.

The combination was studied in research exploring moderate acne vulgaris in women who also require contraception. Research consisted of Randomized Controlled Trials (RCTs), where the medicine was often compared against a placebo. Research examined outcomes linked to inflammatory or irritative states, specifically counting the reduction in both inflammatory lesions (e.g., papules, pustules) and total lesions. Additionally, studies monitored the overall skin condition using standardized scales like the Investigator Global Assessment (IGA).

Research examined changes measured during the study period for the count of acne lesions. Studies reported patterns related to the percentage of participants whose skin condition was documented at a predetermined level on the IGA scale. The results apply only to the populations studied, which are primarily women with mild to moderate acne. Comparative evidence is lacking for a direct, head-to-head comparison against all non-hormonal standard treatments for acne.

Research Gaps and Areas of Uncertainty

Evidence highlights what is known—and what is still uncertain. A primary research gap is the limited information for long-term outcomes across all indications, particularly concerning the durability of acne improvement. The comparative evidence is lacking for head-to-head trials against all possible alternative therapeutic options for the secondary indications.

Finally, data for certain groups remain insufficient, such as those with significant pre-existing comorbidities or different body mass indexes, and subgroup findings are uncertain. Research is ongoing to address these uncertainties.

Key Studies & References Pharmacology of dienogest: a new-generation progestin

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Жанин (FAQ)


Q: How does the combination of hormones in Жанин differ from progestin-only pills?

Жанин is a combined oral contraceptive (COC), meaning it contains two types of hormones: an estrogen and a progestogen. Official sources note that this combination primarily prevents pregnancy by suppressing ovulation (the release of an egg). This mechanism differs from progestogen-only pills, which rely mostly on thickening the cervical mucus to block sperm movement.


Q: How long after starting the pack does Жанин typically begin to prevent pregnancy?

According to regulatory guidelines, if a person starts taking the medication on the very first day of their menstrual period, contraceptive protection is generally considered to be established immediately. If administration begins later in the cycle, official guidance recommends the use of a non-hormonal back-up method for the first seven days of active tablet administration.


Q: Is a delay of a few hours in taking Жанин considered a missed pill according to official guidelines?

Official prescribing instructions state that a delay of less than 12 hours from the scheduled time is typically not considered a missed dose, and effectiveness is maintained. If the delay is 12 hours or longer, it is officially classified as a missed dose, and the user should refer to the specific official instructions regarding missed pills.


Q: What are the official guidelines for managing breakthrough bleeding while taking Жанин?

Regulatory documents indicate that unscheduled bleeding (spotting or bleeding outside of the hormone-free week) is common, particularly during the first three months of use. Official guidance usually describes continuing the tablets as scheduled. If the bleeding is heavy or persistent, it is described as necessary to seek medical consultation to rule out other potential causes.


Q: What kind of visual disturbances, if any, are described in the regulatory documents for Жанин?

Official safety information states that visual disturbances can occur as an uncommon or rare side effect of combined oral contraceptives. More significantly, a sudden partial or complete loss of vision is listed as a potential symptom of a serious, rare side effect like an arterial blood clot event.


Q: What are the official recommendations if a person experiences vomiting or severe diarrhea while on Жанин?

If severe vomiting or diarrhea occurs within 3 to 4 hours after taking an active tablet, regulatory recommendations state that the absorption of the hormones may be incomplete. Regulatory recommendations describe treating this event as a missed pill, often involving immediate administration of a replacement active tablet and continuation of the regular schedule.


Q: Are there specific categories of common over-the-counter medications that may interact with Жанин?

Regulatory documents mention that substances which accelerate hormone clearance, such as the herbal product St. John’s Wort, can reduce the effectiveness of the pill. However, official drug interaction information generally does not list common over-the-counter pain relievers or cold medications as having clinically significant interactions.


Q: Does the age of the user influence the safety profile of Жанин, according to research?

Yes. Official contraindications emphasize that the risk of serious cardiovascular events, such as blood clots, increases with age. For this reason, the use of Жанин is generally listed as contraindicated for women aged 35 years and older who smoke.


Q: Can a person extend the time between pill packs by skipping the inactive tablets of Жанин?

Yes, according to official dosing guidelines, a person may choose to delay their withdrawal bleed by skipping the inactive (hormone-free) tablets and immediately starting a new pack of active tablets. This is an acknowledged option for use, provided the correct steps are followed to maintain contraceptive protection.


Q: What is the potential impact on contraceptive effectiveness if several pills are missed near the beginning of a pack?

Missing two or more active pills significantly increases the risk of pregnancy, especially when missed at the beginning of the cycle. Regulatory instructions for this situation typically mandate the use of a non-hormonal barrier method for seven consecutive days after the last missed tablet.


Q: Is it normal to have no withdrawal bleed (amenorrhea) when taking Жанин, and what does official guidance say?

Having no withdrawal bleed (amenorrhea) is a known possibility due to the hormonal suppression caused by combined oral contraceptives, even with correct use. Official guidance states that ruling out pregnancy is required if two consecutive withdrawal bleeds are missed, even if all pills were taken correctly.


Q: Do official prescribing texts contain information on whether Жанин can be used continuously without a break?

While the standard packaging dictates a 21-day active phase followed by a hormone-free interval, official guidelines acknowledge and regulate the concept of using the active pills continuously or in an extended cycle. This practice is recognized as an option for delaying the regular withdrawal bleed.


Q: What are the known descriptive effects of Жанин on blood pressure levels?

According to official warnings, a slight increase in blood pressure has been reported in women using combined oral contraceptives. Due to this effect and the potential to worsen existing conditions, the medication is listed as a contraindication for individuals with uncontrolled hypertension.


Q: What is the official term for the type of period that occurs during the pill-free week of Жанин?

The bleeding that occurs during the pill-free interval is officially termed a withdrawal bleed or withdrawal bleeding in regulatory documents. This bleeding is not a natural menstrual period but is instead caused by the withdrawal of the synthetic hormones.


Q: Can the effectiveness of Жанин be reduced by certain medical conditions, regardless of pill-taking schedule?

Yes, official safety information indicates that effectiveness may be reduced by medical conditions that compromise hormone absorption or metabolism. Examples include severe conditions resulting in vomiting or diarrhea, or certain forms of severe liver impairment that affect hormone clearance.


Q: Do official sources describe any typical expectations for how long it takes for fertility to return after stopping Жанин?

Official patient leaflets often state that the return to normal reproductive function is generally rapid after discontinuation. Most women who stop using combined oral contraceptives can expect their fertility to return quickly, often within the first menstrual cycle.


Q: Are there any studies examining the use of Жанин in people with a history of migraines?

Regulatory documents provide specific warnings and contraindications related to migraines. The use of combined oral contraceptives is listed as contraindicated in women with a history of migraine with focal neurological symptoms (aura) because it is associated with an increased risk of stroke.


Q: What are the descriptive signs mentioned in official documents that could indicate a serious side effect while on Жанин?

Official patient information describes that symptoms which may indicate a serious adverse reaction should prompt an immediate medical consultation. Warning signs include sudden severe chest pain, unexplained swelling or pain in a leg, sudden shortness of breath, or unusually severe and prolonged headaches.


Q: What level of efficacy is generally associated with combined oral contraceptives like Жанин when used as directed?

Regulatory clinical trials use a standardized measure called the Pearl Index to report efficacy. Clinical trials, using the Pearl Index, typically cite a pregnancy rate of less than 1 per 100 women-years for perfect use.

Advertisements

How should Жанин be stored and disposed of?

How to Store and Dispose of Жанин? (Official Regulatory Information)

The storage and handling of Жанин (dienogest/ethinyl estradiol) must follow specific regulatory requirements to maintain the product's stability and integrity.

Requirement Type Official Condition
Temperature Store at a temperature not exceeding 25°C (77°F).
Protection Keep in the original package to protect from light and moisture.
Handling Keep out of the sight and reach of children.

Disposal of unused or expired medicine must comply with regulatory environmental mandates. The product should not be disposed of in household waste or wastewater. Instead, it must be returned to a pharmacist or local collection point for appropriate handling as pharmaceutical waste, according to local government requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Жанин found in:

A-Z Index: